Reach Separations

Executive Summary

Reach Separations is a UK-based contract research organization (CRO) specializing in high-performance liquid chromatography (HPLC) and supercritical fluid chromatography (SFC) for small molecule purification and analysis. Founded in 2018 and headquartered in Cambridge, the company focuses on chiral separations, serving pharmaceutical, agrochemical, and fine chemical clients. By offering rapid, high-quality purification services, Reach Separations addresses the growing demand for enantiomerically pure compounds in drug development and manufacturing. The company's expertise in both HPLC and SFC positions it well to capitalize on the increasing complexity of small molecule therapeutics, particularly as regulatory scrutiny on chiral purity intensifies. As a private CRO with no disclosed funding, Reach Separations likely operates on a service-revenue model, benefiting from outsourcing trends in the pharmaceutical industry. Its location in Cambridge, a major biotech hub, provides access to a steady pipeline of clients. However, the company faces competition from larger CROs with broader capabilities. Future growth may hinge on expanding its technology platform or forming strategic partnerships with drug developers. The company's lean structure and specialized focus could enable agility, but scaling may require investment. Overall, Reach Separations appears well-positioned in its niche, though its small size limits market share.

Upcoming Catalysts (preview)

• Q4 2026Partnership with a major pharmaceutical company for chiral purification services40% success
• Q2 2027Expansion of SFC capacity to handle larger-scale purifications50% success
• TBDAdoption of new regulatory guidelines requiring enhanced chiral purity testing70% success